SMAD3 and non-small cell lung carcinoma: revealed that Smad3 activation in TANs is associated with the predominant N2 polarization status and poor prognosis of non-small cell lung carcinoma (NSCLC) patients, while they proposed CD16b/iNOS and CD16b/CD206 as markers to identify human N1 and N2 TANs (139).